BC Extra | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

Epigenetics company Epizyme Inc . (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed Inc. (NASDAQ:INSM). Disarm Therapeutics Inc. (Cambridge, Mass.), which is focused on therapies for axonal degeneration, hired Alvin...
BC Week In Review | Dec 21, 2018
Clinical News

Response rate falls for Idera's TLR9 agonist plus Yervoy combo in melanoma

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) reported updated data showing that tilsotolimod (IMO-2125) plus Yervoy ipilimumab led to a lower overall response rate (ORR) in metastatic melanoma patients than what the company reported at this year's American...
BC Extra | Dec 14, 2018
Clinical News

Idera down on melanoma response data

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) lost $2.62 (40%) to $3.98 on Friday after reporting updated data showing that tilsotolimod (IMO-2125) plus Yervoy ipilimumab led to a lower overall response rate (ORR) in metastatic melanoma patients than...
BC Extra | Nov 15, 2018
Company News

Management tracks: Ascletis, Agenus

Antiviral company Ascletis Pharma Inc. (HKSE:1672) hired Lindi Tan as CFO. She was a global healthcare analyst at SeaTown Holdings International. Ascletis was the first biotech to go public on the Hong Kong stock exchange's...
BC Extra | Sep 11, 2018
Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP...
BC Innovations | Aug 30, 2018
Translation in Brief

Turning off the inflammasome

In a July Nature paper , a team from the University of California San Diego identified CMPK2 as a potential target for inflammatory diseases involving NLRP3 inflammasomes and may launch a spinout to develop the findings....
BC Week In Review | Aug 3, 2018
Clinical News

Idera's IMO-8400 misses in Phase II for dermatomyositis

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) reported in June that IMO-8400 missed the primary endpoint vs. placebo in a Phase II trial to treat dermatomyositis in adults. The double-blind, international enrolled 30 patients and evaluated the change...
BC Week In Review | Jul 13, 2018
Company News

BioCryst, Idera drop merger plans

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said it terminated its merger agreement with Idera Pharmaceuticals Inc. (NASDAQ:IDRA) after BioCryst stockholders failed to approve the merger in a special meeting held on July 10. The partners announced the...
BC Extra | Jul 10, 2018
Company News

BioCryst, Idera drop merger plans

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said it terminated its merger agreement with Idera Pharmaceuticals Inc. (NASDAQ:IDRA) after BioCryst stockholders failed to approve the merger in a special meeting held Tuesday. The partners announced the news after...
BC Week In Review | Jun 5, 2018
Clinical News

Idera's TLR9 agonist plus Yervoy leads to 38% ORR in melanoma

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) reported data from 21 evaluable metastatic melanoma patients who progressed on anti-PD-1 therapy in the Phase II portion of the Phase I/II ILLUMINATE-204 (2125-204) trial showing that 8 mg/kg intratumoral tilsotolimod...
Items per page:
1 - 10 of 384
BC Extra | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

Epigenetics company Epizyme Inc . (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed Inc. (NASDAQ:INSM). Disarm Therapeutics Inc. (Cambridge, Mass.), which is focused on therapies for axonal degeneration, hired Alvin...
BC Week In Review | Dec 21, 2018
Clinical News

Response rate falls for Idera's TLR9 agonist plus Yervoy combo in melanoma

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) reported updated data showing that tilsotolimod (IMO-2125) plus Yervoy ipilimumab led to a lower overall response rate (ORR) in metastatic melanoma patients than what the company reported at this year's American...
BC Extra | Dec 14, 2018
Clinical News

Idera down on melanoma response data

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) lost $2.62 (40%) to $3.98 on Friday after reporting updated data showing that tilsotolimod (IMO-2125) plus Yervoy ipilimumab led to a lower overall response rate (ORR) in metastatic melanoma patients than...
BC Extra | Nov 15, 2018
Company News

Management tracks: Ascletis, Agenus

Antiviral company Ascletis Pharma Inc. (HKSE:1672) hired Lindi Tan as CFO. She was a global healthcare analyst at SeaTown Holdings International. Ascletis was the first biotech to go public on the Hong Kong stock exchange's...
BC Extra | Sep 11, 2018
Company News

Management tracks: Cheng joins Akero, bluebird COO leaving

Metabolic company Akero Therapeutics Inc. (Cambridge, Mass.) named former Gilead Sciences Inc. (NASDAQ:GILD) executive Andrew Cheng president and CEO. Cheng joined Gilead in 1999 to lead its development programs in HIV/AIDS and became an EVP...
BC Innovations | Aug 30, 2018
Translation in Brief

Turning off the inflammasome

In a July Nature paper , a team from the University of California San Diego identified CMPK2 as a potential target for inflammatory diseases involving NLRP3 inflammasomes and may launch a spinout to develop the findings....
BC Week In Review | Aug 3, 2018
Clinical News

Idera's IMO-8400 misses in Phase II for dermatomyositis

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) reported in June that IMO-8400 missed the primary endpoint vs. placebo in a Phase II trial to treat dermatomyositis in adults. The double-blind, international enrolled 30 patients and evaluated the change...
BC Week In Review | Jul 13, 2018
Company News

BioCryst, Idera drop merger plans

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said it terminated its merger agreement with Idera Pharmaceuticals Inc. (NASDAQ:IDRA) after BioCryst stockholders failed to approve the merger in a special meeting held on July 10. The partners announced the...
BC Extra | Jul 10, 2018
Company News

BioCryst, Idera drop merger plans

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said it terminated its merger agreement with Idera Pharmaceuticals Inc. (NASDAQ:IDRA) after BioCryst stockholders failed to approve the merger in a special meeting held Tuesday. The partners announced the news after...
BC Week In Review | Jun 5, 2018
Clinical News

Idera's TLR9 agonist plus Yervoy leads to 38% ORR in melanoma

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) reported data from 21 evaluable metastatic melanoma patients who progressed on anti-PD-1 therapy in the Phase II portion of the Phase I/II ILLUMINATE-204 (2125-204) trial showing that 8 mg/kg intratumoral tilsotolimod...
Items per page:
1 - 10 of 384